| Property | Value |
|---|
|
?:abstract
|
-
BACKGROUND/AIM The aim of this descriptive article is to share the experience in Ege University, Turkey with favipiravir in the treatment of severe SARS CoV-2 pneumonia. MATERIALS AND METHODS This retrospective descriptive study included patients diagnosed with COVID-19 who presented with or developed severe pneumonia. RESULTS Forty patients who completed a full course (at least 5 days) of favipiravir were included in the study. At baseline, 30 (75%) patients required treatment for respiratory distress. Thirty three patients (82.5%) were discharged from the hospital with full recovery, 6 patients (15%) died and 1 case (2.5%) was still at the ICU when this paper was written. CONCLUSION This study provides relevant information for the treatment of COVID-19, suggesting that favipiravir was associated with significant clinical and laboratory improvements in the majority of the patients, is a safe drug with no serious side effects and would merit further investigation.
|
|
is
?:annotates
of
|
|
|
?:creator
|
|
|
?:doi
|
|
|
?:doi
|
|
|
?:journal
|
-
Turkish_journal_of_medical_sciences
|
|
?:license
|
|
|
?:pmid
|
|
|
?:pmid
|
|
|
?:publication_isRelatedTo_Disease
|
|
|
is
?:relation_isRelatedTo_publication
of
|
|
|
?:source
|
|
|
?:title
|
-
Treatment of SARS-cov-2 pneumonia with favipiravir: Early results from the Ege University cohort, Turkey.
|
|
?:type
|
|
|
?:year
|
|
![[This page as RDF]](https://research.tib.eu/covid-19/static/rdf-icon.gif){kind=icon}